Ventyx Biosciences plans to launch a Phase 2a clinical trial testing VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3 protein, in people with early Parkinson’s disease in the second half of this year. Top-line results from a Phase 1 study in healthy…
An artificial intelligence (AI)-based software called NetraAI was able to separate subgroups of Parkinson’s disease patients based on their gene activity patterns, helping to better understand the complex pathways that contribute to the neurodegenerative disease. Through the analysis, scientists identified immune signaling as an important disease-related process. The function…
Monte Rosa Therapeutics is running preclinical studies testing MRT-8102, an orally available molecular glue degrader that targets NEK7, a protein needed to set off a type of inflammatory response involved in diseases including Parkinson’s. The studies are a key step in the process of seeking approval for clinical…
Allyx Therapeutics will advance into Phase 2 clinical development of ALX-001, its investigational therapy for neurodegenerative conditions, in people with Parkinson’s disease. The company announced the move alongside the presentation of positive data from a Phase 1b study (NCT05804383) at the International Conference on Alzheimer’s and…
Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…
An antibody that targets a naturally occurring modified form of alpha-synuclein, a protein that forms into toxic clumps in the brain of people with Parkinson’s, delays its buildup and spread in vivo in a mouse model of the disease. This modified form of nitrated alpha-synuclein is being explored by…
An experimental therapy called ASHA-091, which was seen to restore normal mitochondria function and possibly be disease modifying in a mouse model of Parkinson’s disease, may soon be moving into clinical trials, its developer, Asha Therapeutics, reports. Problems with the workings of mitochondria, a cell’s…
NodThera’s potential oral therapy for Parkinson’s disease, NT-0796, continues to show promise in countering damaging inflammation in treated patients, according to new findings from a Phase 1b/2a clinical trial. Treatment with NT-0796 for 28 days safely reduced pro-inflammatory markers in the patients’ cerebrospinal fluid (CSF, the liquid surrounding…
Risvodetinib, an oral therapy being developed by Inhibikase Therapeutics for Parkinson’s disease, appears to stabilize disease status and severity, according to data covering 25 patients who finished 12 weeks of dosing in an ongoing Phase 2 clinical trial. Over those trial weeks, clinician and patient impressions of disease…
Treatment with UB-312, a vaccine designed to trigger an immune response against toxic clumps of the alpha-synuclein protein, reduced these damaging aggregations in people with Parkinson’s disease in a Phase 1 trial. The findings, announced by UB-312’s developer Vaxxinity and presented at the at the AD/PD 2024…
Get regular updates to your inbox.
